Literature DB >> 6438984

Morphological alterations in blood and bone marrow of ribavirin-treated monkeys.

T M Cosgriff, L A Hodgson, P G Canonico, J D White, M D Kastello, J C Donovan, P E Ross.   

Abstract

The antiviral drug ribavirin (1, beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) produced significant hematologic effects when administered to rhesus monkeys by intramuscular injection over 10 days in doses of 30 or 100 mg/kg/day. The monkeys developed dose-related progressive anemia and thrombocytosis associated with marrow erythroid hypoplasia and megakaryocyte hyperplasia. In addition, bone marrow examination revealed phagocytosis of erythroid elements by histiocytes; vacuolization of erythroid precursors, and to a lesser extent precursors of other cell types; and occasional erythroid precursors with megaloblastoid appearance. The alterations were transient and disappeared on discontinuation of the drug.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6438984     DOI: 10.1159/000206386

Source DB:  PubMed          Journal:  Acta Haematol        ISSN: 0001-5792            Impact factor:   2.195


  4 in total

Review 1.  Hemorrhagic fever of bunyavirus etiology: disease models and progress towards new therapies.

Authors:  Brian B Gowen; Brady T Hickerson
Journal:  J Microbiol       Date:  2017-02-28       Impact factor: 3.422

Review 2.  Vitamin D and chronic hepatitis C: effects on success rate and prevention of side effects associated with pegylated interferon-α and ribavirin.

Authors:  Bassem Refaat; Adel Galal El-Shemi; Ahmed Ashshi; Esam Azhar
Journal:  Int J Clin Exp Med       Date:  2015-07-15

3.  Ribavirin induced anaemia: the effect of vitamin D supplementation on erythropoietin and erythrocyte indices in normal Wistar rat.

Authors:  Bassem Refaat; Tariq Helal Ashour; Adel Galal El-Shemi
Journal:  Int J Clin Exp Med       Date:  2014-09-15

4.  Toxicologic effects of ribavirin in cats.

Authors:  R C Weiss; N R Cox; M K Boudreaux
Journal:  J Vet Pharmacol Ther       Date:  1993-09       Impact factor: 1.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.